【打印本页】 【下载PDF全文】 【HTML】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 1793次   下载 1763 本文二维码信息
码上扫一扫!
肝癌患者血清高迁移率族蛋白B1的表达及与p53和临床病理的相关性
陈科济,范飞,朱斌,马优钢,张永杰*
0
(第二军医大学东方肝胆外科医院胆道二科,上海 200438
共同第一作者
*通信作者)
摘要:
目的 探讨肝癌血清高迁移率族蛋白B1(HMGB-1)的表达及与p53的相关性和临床病理特征的关系。方法 酶联免疫吸附剂测定法(ELISA)检测20例肝细胞癌、20例肝内胆管细胞癌患者和20例健康志愿者血清HMGB-1和p53表达。结果 血清HMGB-1在肝细胞癌组\[(83.8±17.4) ng/ml\]和胆管细胞癌组\[(95.9±21.4) ng/ml\]的表达均高于健康对照组\[(8.4±2.6) ng/ml\],差异均有统计学意义(P<0.05);血清p53在肝细胞癌组\[(251.0±45.6) pg/ml\]和胆管细胞癌组\[(267.8±47.4) pg/ml\]的表达均高于健康对照组\[(160.0±28.4) pg/ml\],差异均有统计学意义(P<0.05)。HMGB-1和p53的表达在肝细胞癌组和肝内胆管细胞癌组血清中均呈正相关(r=0.660 3,P<0.05;r=0.614 2,P<0.05);血清HMGB-1和p53水平与患者年龄、性别、肿瘤大小和肿瘤数目无相关性(P>0.05),与肿瘤TNM分期、分化程度、淋巴转移情况相关(P<0.05)。结论 肝癌血清HMGB-1的表达与p53具有相关性,二者共同影响肝癌临床病理。
关键词:  肝肿瘤  HMGB-1蛋白质  肿瘤抑制蛋白质p53  临床病理学;酶联免疫吸附测定
DOI:10.3724/SP.J.1008.2012.0103
投稿时间:2011-08-05修订日期:2011-12-07
基金项目:
Serum HMGB-1 level and its correlation with p53 and clinical pathology in patients with liver cancer
CHEN Ke-ji,FAN Fei,ZHU Bin,MA You-gang,ZHANG Yong-jie*
(Department of Biliary Surgery Ⅱ, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China
Co-first authors.
*Corresponding author.)
Abstract:
Objective To investigate the serum level of high mobility group box-1(HMGB-1) in patients with liver cancer and its correlation with p53 and clinical pathological features of liver cancer. Methods Serum levels of HMGB-1 and p53 were determined by ELISA in 20 patients with hepatocellular carcinoma, 20 with cholangiocellular carcinoma and 20 healthy volunteers. Results Serum HMGB-1 levels in hepatocellular carcinoma patients ([83.8±17.4] ng/ml) and cholangiocellular carcinoma patients ([95.9±21.4] ng/ml) were significantly higher than that in the healthy volunteers ([8.4±2.6] ng/ml, P<0.05). Serum p53 levels in hepatocellular carcinoma patients ([251.0±45.6] pg/ml) and cholangiocellular carcinoma patients ([267.8±47.4] pg/ml) were also significantly higher than that in the healthy volunteers ([160.0±28.4] pg/ml, P<0.05). Serum HMGB-1 level was positively correlated with the serum p53 level in the hepatocellular carcinoma patients (r=0.660 3, P<0.05) and cholangiocellular carcinoma patients (r=0.614 2, P<0.05). Serum HMGB-1 and p53 levels were not correlated with the age, gender, tumor size, or number of tumors (P>0.05), but were correlated with the TNM stage, differentiation degree and metastasis status (P<0.05).Conclusion Serum HMGB-1 level is positively correlated with p53, and both HMGB-1 and P53 influence the pathogenesis of liver cancer.
Key words:  liver neoplasms  HMGB-1 protein  tumor suppressor protein p53  clinical pathology  enzyme-linked immunosorbent assay